Rankiteo Logo
Rankiteo
Leader in Cyber Underwriting
Loading...
NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop
WindowsmacOSLinux
Download

Comparison Overview

Molecular Devices ChinaMolecular Devices China
VS
AmgenAmgen
Molecular Devices China

Molecular Devices China

长宁区福泉北路, 上海, 200335, CN

Last Update: 01/12/2025

View Profile
751/1000Fair

Molecular Devices始创于上世纪80年代美国硅谷,作为全球高通量仪器设备的优秀品牌,一直致力于为生命科学研究及药物研发提供先进的解决方案。其产品覆盖微孔板检测分析、高通量筛选、高内涵成像、高效克隆筛选等。公司以持续创新、快速高效、高质量的产品及完善的售后服务著称业内。 Molecular Devices为您提供高性能的分析检测系统,加快和改进药物研发及基础生命科学的研究。我们的产品除了用于科研单位和部门外,还帮助制药和生物技术企业从分子、细胞和系统水平去了解各项生物功能,研究开发新的治疗方法。 Molecular Dev...

NAICS:541714
NAICS Definition:Research and Development in Biotechnology (except Nanobiotechnology)
Employees:None
Subsidiaries:67
12-month incidents
0
Known data breaches
0
Attack type number
0
Amgen

Amgen

One Amgen Center Drive, Thousand Oaks, CA, US, 91320

Last Update: 05/07/2026

View Profile
Between 800 and 849
http://www.amgen.com
821/1000Good

Amgen harnesses the best of biology and technology to fight the world’s toughest diseases, and make people’s lives easier, fuller and longer. We helped establish the biotechnology industry, and we remain on the cutting-edge of innovation, using technology and human gene...

NAICS:541714
NAICS Definition:Research and Development in Biotechnology (except Nanobiotechnology)
Employees:39,570
Subsidiaries:4
12-month incidents
0
Known data breaches
1
Attack type number
1

Compliance Ranges Comparison

Based On Specific Ai Models Category
Molecular Devices China

Molecular Devices China

-
ISO 27001Not verified
ISO 27001
-
SOC2 Type 1Not verified
SOC2 Type 1
-
SOC2 Type 2Not verified
SOC2 Type 2
-
GDPRNot verified
GDPR
-
PCI DSSNot verified
PCI DSS
-
HIPAANot verified
HIPAA
Amgen

Amgen

-
ISO 27001Not verified
ISO 27001
-
SOC2 Type 1Not verified
SOC2 Type 1
-
SOC2 Type 2Not verified
SOC2 Type 2
-
GDPRNot verified
GDPR
-
PCI DSSNot verified
PCI DSS
-
HIPAANot verified
HIPAA

Benchmark & Cyber Underwriting Signals

Incidents vs Biotechnology Research Industry Avg (This Year)

No incidents recorded for Molecular Devices China in 2026.

Incidents

Incidents vs Biotechnology Research Industry Avg (This Year)

No incidents recorded for Amgen in 2026.

Incidents

Incident History - Molecular Devices China (X = Date, Y = Severity)

Molecular Devices China cyber incidents detection timeline including parent company and subsidiaries.

No timeline data available
R - Ransomware
C - Cyber Attack
D - Data Breach
V - Vulnerability

Incident History - Amgen (X = Date, Y = Severity)

Amgen cyber incidents detection timeline including parent company and subsidiaries.

R - Ransomware
C - Cyber Attack
D - Data Breach
V - Vulnerability

Notable Incidents

Last Cyber / HR Incidents / Global...
Molecular Devices China

Molecular Devices China

Incidents
No explicit notable incidents reported.
Amgen

Amgen

Incidents
🔒 Incident : Breach
AMG552072825

FAQ

Between Molecular Devices China company and Amgen company, which one has the best AI Cybersecurity Score ?
Between Molecular Devices China company and Amgen company, which one has experienced more cyber incidents in the past ?
Between Molecular Devices China company and Amgen company, which one has experienced more cyber incidents this year ?
Between Molecular Devices China company and Amgen company, which one has experienced at least one ransomware attack ?
Between Molecular Devices China company and Amgen company, which one has experienced at least one data breach ?
Between Molecular Devices China company and Amgen company, which one has experienced at least one targeted cyberattack ?
Between Molecular Devices China company and Amgen company, which one has experienced at least one vulnerability ?
Between Molecular Devices China company and Amgen company, which one holds the most compliance certifications ?
Between Molecular Devices China company and Amgen company, which one holds the fewest compliance certifications ?
Between Molecular Devices China company and Amgen company, which one has the most subsidiaries ?
Between Molecular Devices China company and Amgen company, which one has the largest number of employees ?
Between Molecular Devices China and Amgen, which company holds both SOC 2 Type 1 certifications ?
Between Molecular Devices China and Amgen, which company holds both SOC 2 Type 2 certifications ?
Which company is ISO 27001 certified - Molecular Devices China or Amgen ?
Which company is PCI DSS compliant - Molecular Devices China or Amgen ?
Between Molecular Devices China and Amgen, which company complies with HIPAA regulations for healthcare data ?
Between Molecular Devices China and Amgen, which company complies with GDPR requirements ?

Latest Global CVEs

CVE-2026-63261
SUMMARY

Uncontrolled Resource Consumption (CWE-400) in Kibana can lead to denial of service via Excessive Allocation (CAPEC-130). A low-privileged authenticated user can send a specially crafted request to a Kibana machine learning feature, causing the server to exhaust available memory and become unavailable to all users.

PUBLISHED
Date2026-07-21
UPDATED
Date2026-07-21
RISK INFORMATION (Score: 6.5)
CVSS3
Base Score: 6.5
Complexity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:N/I:N/A:H
IMPACT SCORE
3.6
EXPLOITABILITY
2.8
CVE-2026-63260
SUMMARY

Uncontrolled Resource Consumption (CWE-400) in Kibana can lead to denial of service via Excessive Allocation (CAPEC-130). An authenticated attacker with low-privilege access can trigger a denial of service condition in Kibana by sending a specially crafted, oversized request payload. Processing this user-supplied input requires resource-intensive memory allocation that can exhaust the available heap memory in the Kibana process, causing it to crash and become unavailable to all users.

PUBLISHED
Date2026-07-21
UPDATED
Date2026-07-21
RISK INFORMATION (Score: 6.5)
CVSS3
Base Score: 6.5
Complexity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:N/I:N/A:H
IMPACT SCORE
3.6
EXPLOITABILITY
2.8
CVE-2026-63259
SUMMARY

Authorization Bypass Through User-Controlled Key (CWE-639) in Kibana can lead to information disclosure via user-supplied identifiers that reference scheduled query result data from Kibana Spaces the requester is not authorized to access.

PUBLISHED
Date2026-07-21
UPDATED
Date2026-07-21
RISK INFORMATION (Score: 4.3)
CVSS3
Base Score: 4.3
Complexity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:N/A:N
IMPACT SCORE
1.4
EXPLOITABILITY
2.8
CVE-2026-63145
SUMMARY

Incorrect Authorization (CWE-863) in Kibana can lead to integrity compromise of Machine Learning audit and notification records via Accessing Functionality Not Properly Constrained by ACLs (CAPEC-1). A vulnerability exists in Kibana's Machine Learning functionality where a Machine Learning management endpoint performs an insufficient authorization check. The endpoint validates only a coarse privilege level but does not verify that the requesting user has access to the specific Machine Learning job or notification resources provided in the request. As a result, a low-privileged user with Machine Learning access in any Kibana space can manipulate Machine Learning audit and notification records for arbitrary jobs—including jobs in other spaces or belonging to other users—by leveraging Kibana's internally elevated credentials to write to restricted Machine Learning system indices that the user cannot access directly.

PUBLISHED
Date2026-07-21
UPDATED
Date2026-07-21
RISK INFORMATION (Score: 4.3)
CVSS3
Base Score: 4.3
Complexity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:N/I:L/A:N
IMPACT SCORE
1.4
EXPLOITABILITY
2.8
CVE-2026-63144
SUMMARY

Uncontrolled Recursion (CWE-674) in Elasticsearch can lead to denial of service via a specially crafted search request submitted by a low-privileged authenticated user. A user with read-level index access can submit a request that triggers unbounded recursive processing within the Elasticsearch query evaluation component, causing a fatal error that terminates the affected node. In single-node deployments, this results in complete service outage; in multi-node clusters, it causes repeated node restarts and sustained availability degradation.

PUBLISHED
Date2026-07-21
UPDATED
Date2026-07-21
RISK INFORMATION (Score: 6.5)
CVSS3
Base Score: 6.5
Complexity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:N/I:N/A:H
IMPACT SCORE
3.6
EXPLOITABILITY
2.8